INNOCARE Shares Rise Nearly 3% on ASCO 2026 Oral Presentation Selection for Mesutoclax Study

Stock News04-28 09:56

INNOCARE (09969) saw its shares increase by nearly 3%. At the time of writing, the stock was up 2.67%, trading at HK$14.24 with a turnover of HK$29.20 million. The movement follows an announcement from the company on April 27, via its official social media channels, that multiple research findings related to its self-developed novel BCL2 inhibitor Mesutoclax (ICP-248) and novel BTK inhibitor orelabrutinib have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Notably, the study on Mesutoclax for the treatment of myeloid malignancies was chosen for an oral presentation, while research on Mesutoclax for B-cell malignancies was selected for a poster presentation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116977360?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 09:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116977360","market":"us","top_or_hot":-1,"title":"INNOCARE Shares Rise Nearly 3% on ASCO 2026 Oral Presentation Selection for Mesutoclax Study","media":"Stock News","content":"<p>INNOCARE (09969) saw its shares increase by nearly 3%. At the time of writing, the stock was up 2.67%, trading at HK$14.24 with a turnover of HK$29.20 million. The movement follows an announcement from the company on April 27, via its official social media channels, that multiple research findings related to its self-developed novel BCL2 inhibitor Mesutoclax (ICP-248) and novel BTK inhibitor orelabrutinib have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Notably, the study on Mesutoclax for the treatment of myeloid malignancies was chosen for an oral presentation, while research on Mesutoclax for B-cell malignancies was selected for a poster presentation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOCARE Shares Rise Nearly 3% on ASCO 2026 Oral Presentation Selection for Mesutoclax Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOCARE Shares Rise Nearly 3% on ASCO 2026 Oral Presentation Selection for Mesutoclax Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-28 09:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOCARE (09969) saw its shares increase by nearly 3%. At the time of writing, the stock was up 2.67%, trading at HK$14.24 with a turnover of HK$29.20 million. The movement follows an announcement from the company on April 27, via its official social media channels, that multiple research findings related to its self-developed novel BCL2 inhibitor Mesutoclax (ICP-248) and novel BTK inhibitor orelabrutinib have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Notably, the study on Mesutoclax for the treatment of myeloid malignancies was chosen for an oral presentation, while research on Mesutoclax for B-cell malignancies was selected for a poster presentation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1116977360","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116977360","pubTimestamp":1777341385,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOCARE (09969) saw its shares increase by nearly 3%. At the time of writing, the stock was up 2.67%, trading at HK$14.24 with a turnover of HK$29.20 million. The movement follows an announcement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard","BK0239":"医药制造","09969":"诺诚健华","BK4588":"碎股"},"translate_title":"诺诚健华股价因ASCO 2026 mesutoclax研究口头报告选择而上涨近3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"VXUS":1,"09969":1},"content_text":"INNOCARE (09969) saw its shares increase by nearly 3%. At the time of writing, the stock was up 2.67%, trading at HK$14.24 with a turnover of HK$29.20 million. The movement follows an announcement from the company on April 27, via its official social media channels, that multiple research findings related to its self-developed novel BCL2 inhibitor Mesutoclax (ICP-248) and novel BTK inhibitor orelabrutinib have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Notably, the study on Mesutoclax for the treatment of myeloid malignancies was chosen for an oral presentation, while research on Mesutoclax for B-cell malignancies was selected for a poster presentation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116977360","isCrawlerRequest":true}